Chemistry:Zemprocitinib
From HandWiki
Zemprocitinib is an investigational new drug that is be evaluated by Lynk Pharmaceuticals for the treatment of ankylosing spondylitis and rheumatoid arthritis.[1] It is an janus kinase 1 (JAK1) inhibitor.[2][3]
Clinical trials
It is currently being evaluated in a phase 3 trials trial for the treatment of rheumatoid rthritis.[4]
References
- ↑ "Zemprocitinib - Lynk Pharmaceuticals". AdisInsight. Springer Nature Switzerland AG. https://adisinsight.springer.com/drugs/800063864.
- ↑ "Application of JAK inhibitors in the treatment of rheumatoid arthritis: a systematic analysis based on clinical trial databases and registries". Frontiers in Medicine (Lausanne) 13. 2026. doi:10.3389/fmed.2026.1680115. PMID 41868221.
- ↑ "Smallest Bicycles in Medicinal Chemistry: Where Are We Now?". Chemical Reviews 126 (6): 3829–3882. March 2026. doi:10.1021/acs.chemrev.5c00779. PMID 41818297.
- ↑ Clinical trial number NCT06276998 for "A Study of LNK01001 Capsule in Subjects With Active Rheumatoid Arthritis (COURAGE-RA) " at ClinicalTrials.gov
 |  |
